Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches
home / meeting-of-the-minds / maximizing-outcomes-in-relapsed-refractory-multiple-myeloma-tailoring-bispecific-antibody
Medical experts explore tailored treatment strategies for patients with relapsed/refractory multiple myeloma using bispecific antibodies, featuring expert insights and a patient profile portrayal to guide clinical decision-making.
EP. 1: John’s Journey with R/R MM
Meera Mohan, MD;Areyl Goff, APNP;Hashim Mann, MD;Kevin Brigle, PhD;Omar Nadeem, MD;Alexandra Distaso, NP
December 23rd 202468-year-old male construction worker with a long history of multiple myeloma, managing multiple lines of treatment including BCMA-directed CAR T therapy, alongside a history of hypertension, respiratory infections, and type 2 diabetes, now receiving talquetamab.
EP. 2: MonumenTAL: Key Efficacy Outcomes
Meera Mohan, MD;Areyl Goff, APNP;Hashim Mann, MD;Kevin Brigle, PhD;Omar Nadeem, MD;Alexandra Distaso, NP
December 23rd 2024Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.
